245 related articles for article (PubMed ID: 31568233)
21. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
Cardoso E; Csajka C; Schneider MP; Widmer N
Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
[TBL] [Abstract][Full Text] [Related]
22. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
[TBL] [Abstract][Full Text] [Related]
23. Precision Dosing of Targeted Therapies Is Ready for Prime Time.
Groenland SL; Verheijen RB; Joerger M; Mathijssen RHJ; Sparreboom A; Beijnen JH; Beumer JH; Steeghs N; Huitema ADR
Clin Cancer Res; 2021 Dec; 27(24):6644-6652. PubMed ID: 34548319
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
Marquet P
Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
[TBL] [Abstract][Full Text] [Related]
25. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
Gurney H
J Clin Oncol; 1996 Sep; 14(9):2590-611. PubMed ID: 8823340
[TBL] [Abstract][Full Text] [Related]
26. [Is therapeutic drug monitoring (TDM) in paediatric patients necessary?].
Prokopczyk J; Piekarczyk A; Kaminska E
Med Wieku Rozwoj; 2001; 5(2):149-55. PubMed ID: 11679679
[TBL] [Abstract][Full Text] [Related]
27. Target concentration intervention in oncology: where are we at?
Saleem M; Dimeski G; Kirkpatrick CM; Taylor PJ; Martin JH
Ther Drug Monit; 2012 Jun; 34(3):257-65. PubMed ID: 22585183
[TBL] [Abstract][Full Text] [Related]
28. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacokinet; 2005; 44(2):147-73. PubMed ID: 15656695
[TBL] [Abstract][Full Text] [Related]
29. [Role of individualized dosing in oncology: are we there yet?].
Joerger M
Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
[TBL] [Abstract][Full Text] [Related]
30. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin AM; Schmulenson E; Teplytska O; Zimmermann S; Opitz P; Groenland SL; Huitema ADR; Steeghs N; Müller L; Fuxius S; Illerhaus G; Joerger M; Mayer F; Fuhr U; Holdenrieder S; Hempel G; Scherf-Clavel O; Jaehde U; Kloft C; For The On-Target Study Consortium
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944899
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.
Hiemke C
Eur J Clin Pharmacol; 2008 Feb; 64(2):159-66. PubMed ID: 18196227
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives.
Falkowski S; Woillard JB
Ther Drug Monit; 2019 Oct; 41(5):568-574. PubMed ID: 30913132
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring of non-anticancer drugs in cancer patients.
Joerger M; Schellens JH; Beijnen JH
Methods Find Exp Clin Pharmacol; 2004 Sep; 26(7):531-45. PubMed ID: 15538543
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.
Janssen JM; Dorlo TPC; Steeghs N; Beijnen JH; Hanff LM; van Eijkelenburg NKA; van der Lugt J; Zwaan CM; Huitema ADR
Clin Pharmacol Ther; 2020 Sep; 108(3):494-505. PubMed ID: 32022898
[TBL] [Abstract][Full Text] [Related]
37. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions.
Gala UH; Miller DA; Williams RO
Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188319. PubMed ID: 31678141
[TBL] [Abstract][Full Text] [Related]
38. Conflicting meal recommendations for oral oncology drugs: pose risks to patient care?
Yu G; Wu DN; Gong Y; Li GF; Zhou HH
Eur J Clin Pharmacol; 2018 Jun; 74(6):833-842. PubMed ID: 29536134
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Guchelaar NAD; van Eerden RAG; Groenland SL; Doorn LV; Desar IME; Eskens FALM; Steeghs N; van Erp NP; Huitema ADR; Mathijssen RHJ; Koolen SLW;
Biomed Pharmacother; 2022 Sep; 153():113393. PubMed ID: 35834987
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen SI; Tomson T
Clin Pharmacokinet; 2006; 45(11):1061-75. PubMed ID: 17048972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
